Ossifikationsprozesse als treibende Kräfte für die Krebserkrankung
Der Merkurstab 2019;72(5):364-370.
Artikel-ID: DMS-21142-DE
DOI: https://doi.org/10.14271/DMS-21142-DE
Bei der Krebserkrankung verlagert sich Knochenfunktion aus dem Skelett in den Tumor hinein. Karzinome „verknöchern“ nicht nur substanziell, sondern sind sogar bestrebt, funktionell knochenähnlich zu werden. Aufgrund ihrer pathologisch „ohrartigen“ Konstitution sind sie „Sinnesorgane an falscher Stelle“. Schon vorkonzeptionell stehen Verknöcherung und Krebserkrankung in einer Beziehung, wenn verdichtende Bildekräfte im Hinblick auf die erneute Inkarnation zu stark wirken. Die Krebserkrankung ist konstitutionell durch Sinnes-Nerven- und Ossifikationsprozesse geprägt.
Ossification processes as driving forces for cancer
In the case of cancer disease, bone function is displaced from the skeleton into the tumor. Carcinomas do not only “ossify” substantially, they even functionally strive to become like bone. Because of their pathologically “ear-like” configuration, tumors represent “sense organs at the wrong place”. The relationship between ossification and cancer already begins pre-conceptionally when densifying spiritual forces in correspondence to the next incarnation become predominant. Cancer is driven by sense-nerve- and ossification processes.
1 Steiner R. Geisteswissenschaft und Medizin. GA 312. Vortrag vom 27.03.1920. 5. Aufl. Dornach: Rudolf Steiner Verlag; 1976.
2 Steiner R. Geisteswissenschaft und Medizin. GA 312. Vortrag vom 03.04.1920. 7. Aufl. Dornach: Rudolf Steiner Verlag; 1999.
3 Morgan MP, Cooke MM, McCarthy GM. Microcalcifications associated with breast cancer: an epiphenomenon of biologically significant feature of selected tumors? J Mammary Gland Biol Neoplasia 2005;10(2):181–187. [Crossref]
4 Johannessen JV, Sobrinho-Simões M. The origin and significance of thyroid psammoma bodies. Lab Invest 1980;43(3):287–296.
5 Murayama H, Kamio A, Imai T, Kikuchi M. Gastric carcinoma with psammomatous calcification: report of a case, with reference to calculogenesis. Cancer 1982;49(4):788–796. [Crossref]
6 Chen YJ, Wu CY, Huang YL, et al. Cancer risks of dermatomyositis and polymyositis: a nationwide cohort study in Taiwan. Arthritis Res Ther 2010;12(2):R70. [Crossref]
7 Eckardt JJ, Ivins JC, Perry HO, Unni KK. Osteosarcoma arising in heterotopic ossification of dermatomyositis; case report and review of literature. Cancer 1981;48(5):1256–1261. [Crossref]
8 Picca DA, de Paredes ES. Calcifications in the breast: a radiologic perspective. Appl Radiol 2003;(9):29–37.
9 Baker R, Rogers KD, Shepherd N, Stone N. New relationships between breast microcalcifications and cancer. Brit J Cancer 2010;103:1034–1039. [Crossref]
10 Steiner R. Konferenzen mit den Lehrern der Freien Waldorfschule. Bd. II: Konferenzen 1921–1923. GA 300b. 4. Aufl. Dornach: Rudolf Steiner Verlag; 1975.
11 Steiner R. Physiologisch-Therapeutisches auf Grundlage der Geisteswissenschaft. GA 314. 2. Aufl. Dornach: Rudolf Steiner Verlag; 1975.
12 Schramm HM. Extraterritorial osteoclast traits of primary cancer cells. J Solid Tumors 2011;1(2):65–79. [Crossref]
13 Schramm HM. Should EMT of cancer cells be understood as epithelial-myeloid transition? J Cancer 2014;5(2):125–132. [Crossref]
14 Schramm HM. The role of the osteoimmune axis in the inflammation of the inner auditory ear and with regard to the putative anticarcinogenetic principle. Inflamm Allergy Drug Targets 2010;9(2):120–129. [Crossref]
15 Rucci N, Teti A. Osteomimikry. How tumor cells try to deceive the bone. Front Biosci 2010;S2:907–915. [Crossref]
16 Knerr K, Ackermann K, Neidhart T, Pyerin W. Bone metastasis: osteoblasts affect growth and adhesion regulations in prostate tumor cells and provoke osteomimikry. Int J Cancer 2004;111(1):152–159. [Crossref]
17 Bellahcène A, Castronovo V. Expression de protéines de la matrice osseuse dans les cancers mammaires humains: rôles potentiels dans la formation de microcalcifications et dans la genèse de métastases osseuses. Bulletin du Cancer 1997;84(1):17–24.
18 Brown LF, Papadopoulos-Sergiou A, Berse B, et al. Osteopontin expression and distribution in human carcinomas. Am J Pathol 1994;145(3):610–623.
19 Kolb A, Kleeff J, Guweidhi A, et al. Osteopontin influences the invasiveness of pancreatic cancer cells and is increased in neoplastic and inflammatory conditions. Cancer Biol Ther 2005;4(7):740–746. [Crossref]
20 Yoshidome H, Kohno H, Shida T, et al. Significance of monocyte chemoattractant protein-1 in angiogenesis and survival in colorectal liver metastasis. Int J Oncol 2009;34(4):923–930. [Crossref]
21 Kremer R, Li J, Camirand A, Karaplis AC. Parathyroid hormone related protein (PTHrP) in tumor progression. Adv Exp Med Biol 2011;720:145–160. [Crossref]
22 Imano M, Okuno K, Itoh T, et al. Increased osteopontinpositive macrophage expression in colorectal cancer stroma with synchronous liver metastasis. World J Surg 2010;34(8):1930–1936. [Crossref]
23 Botti G, Scognamiglio G, Marra L, et al. SPARC/osteonectin is involved in metastatic processes to the lung during melanoma progression. Virchows Archiv 2014;465(3):331–338. [Crossref]
24 Powell GJ, Southby J, Danks JA, et al. Localization of parathyroid hormone-related protein in breast cancer metastases: increased incidence in bone compared with other sites. Cancer Res 1991;51(11):3059–3061.
25 Yoshida T, Suzumiya J, Kata - kami H, et al. Hypercalcemia caused by PTH-rP associated with lung metastasis from urinary bladder carcinoma: an autopsied case. Intern Med 1994;33(11):673–676. [Crossref]
26 Tsubochi H, Endo S, Oda Y, Dobashi Y. Carcinoid tumor of the lung with massive calcification: report of a case showing the evidence of osteomimicry and review of the literature. Int J Clin Exp Pathol 2013;6(5):957–961.
27 Kinder M, Chislock E, Bussard KM, et al. Metastatic breast cancer induces an osteoblast inflammatory response. Experim Cell Res 2008;314(1):173–183. [Crossref]
28 Ganry O, Baudoin C, Radellone P, et al. Bone mass density and risk of breast cancer and survival in older women. Eur J Epidem 2004;19(8):785–792. [Crossref]
29 Qu X, Zhang X, Qin A, et al. Bone mineral density and risk of breast cancer in postmenopausal women. Breast Cancer Res Treatm 2013;138(1):261–271. [Crossref]
30 Zhang Y, Kiel DP, Kreger BE, et al. Bone mass and the risk of breast cancer among postmenopausal women. New England J Med 1997;336(9):611–617. [Crossref]
31 Kim BK, Choi YH, Song YM, et al. Bone mineral density and the risk of breast cancer: a case-control study of Korean women. Ann Epidemiol 2014;24(3):222–227. [Crossref]
32 Zmuda JM, Cauley JA, Ljung BM, et al. Bone mass and breast cancer risk in older women: differences by stage at diagnosis. J Nat Cancer Inst 2001;93(12):930–936. [Crossref]
33 Koeneman KS, Yeung F, Chung LWK. Osteomimetic properties of prostate cancer cells: a hypothesis supporting the pre-dilection of prostate cancer metastasis and growth in the bone environment. The Prostate 1999;39(4):246–261. [Crossref]
34 Janane A, Hajji F, Ismail T, et al. Cambios en la densidad mineral ósea: comparación entre pacientes de cancer de prostata con o sin metastasis y varones sanos (grupo étnico norteafricano). Actas Urol Esp 2011;35(7):414–419. [Crossref]
35 Cauley JA, Fullman RL, Stone KL, et al. Factors associated with the lumbar spine and proximal femur bone mineral density in older men. Osteopor Int 2005;16(12):1525–1537. [Crossref]
36 Loeb S, Carter HB, Schaeffer EM, et al. Bone mineral content and prostate cancer risk: data from the Baltimore Longitudinal Study of Aging. Brit J Urol Int 2010;106(1):28–31. [Crossref]
37 Zhang Y, Kiel DP, Ellison RC, et al. Bone mass and the risk of prostate cancer: the Framingham study. Am J Med 2002;113(9):734–739. [Crossref]
38 Chang CH, Tsai CS, Jim YF, et al. Lumbar bone mineral density in prostate cancer patients with bone metastases. Endocr Res 2003;29(2):177–182. [Crossref]
39 Perk H, Yildiz M, Kosar A, et al. Correlation between BMD and bone scintigraphy in patients with prostate cancer. Urol Oncol 2008;26(3):250–253. [Crossref]
40 Gunnarsson O, Basaria S, Gignac GA. Cardiometabolic and skeletal risk factors in black men with prostate cancer starting androgen deprivation therapy. Cancers 2015;7(2):679–687. [Crossref]
41 Smith GL, Doherty AP, Banks LM, et al. Dual X-ray absorptiometry detects disease- and treatment-related alterations of bone density in prostate cancer patients. Clin Exp Metastasis 2000;18(5):385–390. [Crossref]
